Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRM2 | Q14416 | 1/20 | 0.41 |
| ▸ | LCK | P06239 | 2/20 | 0.40 |
| ▸ | PDE4D | Q08499 | 3/20 | 0.40 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 2/20 | 0.38 |
| ▸ | NQO2 | P16083 | 2/20 | 0.37 |
| ▸ | BACE1 | P56817 | 1/20 | 0.37 |
| ▸ | GPR35 | Q9HC97 | 1/20 | 0.37 |
| ▸ | DHODH | Q02127 | 1/20 | 0.35 |
| ▸ | PIM1 | P11309 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1166810 | 0.88 | GPR35 (0.50) | PDE4DMAPK1MAPTGPR35PIM1 | |
| SCHEMBL14919170 | 0.85 | GRM2 (0.42) | GRM2LCKMAPK1MAPTNQO2 | |
| SCHEMBL561626 | 0.85 | GPR35 (0.47) | LCKPDE4DMAPK1MAPTBACE1 | |
| SCHEMBL561469 | 0.84 | PDE4D (0.45) | LCKPDE4DMAPK1MAPTNQO2 | |
| SCHEMBL14393065 | 0.84 | PDE4D (0.35) | PDE4DMAPTGPR35PIM1 | |
| SCHEMBL13074496 | 0.84 | PDE4D (0.42) | LCKPDE4DMAPK1MAPTNQO2 | |
| SCHEMBL12809264 | 0.84 | LCK (0.40) | GRM2LCKPDE4DMAPK1MAPT | |
| SCHEMBL561388 | 0.84 | RXFP1 (0.40) | LCKPDE4DMAPK1MAPTGPR35 | |
| SCHEMBL561666 | 0.81 | PDE10A (0.47) | LCKPDE4DMAPK1MAPT | |
| SCHEMBL2222961 | 0.78 | ADORA2A (0.47) | GRM2LCKMAPK1MAPTNQO2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 39 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-103204903-A | Hepatitis c inhibitor compounds | BOEHRINGER INGELHEIM INT | 2013-07-17 | — | — | CN | disclosed |
| US-20120269769-A1 | Hepatitis C Inhibitor Compounds | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-10-25 | — | — | US | disclosed |
| US-20120269769-A1 | Hepatitis C Inhibitor Compounds | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-10-25 | — | — | US | disclosed |
| US-20120269769-A1 | Hepatitis C Inhibitor Compounds | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-10-25 | — | — | US | disclosed |
| US-20120034187-A1 | Hepatitis C Inhibitor Compounds | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-02-09 | — | — | US | disclosed |
| US-20120034187-A1 | Hepatitis C Inhibitor Compounds | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-02-09 | — | — | US | disclosed |
| US-20120034187-A1 | Hepatitis C Inhibitor Compounds | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-02-09 | — | — | US | disclosed |
| US-8067438-B2 | Hepatitis C inhibitor compounds | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2011-11-29 | — | — | US | disclosed |
| US-8067438-B2 | Hepatitis C inhibitor compounds | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2011-11-29 | — | — | US | disclosed |
| US-8067438-B2 | Hepatitis C inhibitor compounds | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2011-11-29 | — | — | US | disclosed |
| US-20070243166-A1 | Hepatitis C Inhibitor Compounds | LLINAS-BRUNET MONTSE | 2007-10-18 | — | — | US | disclosed |
| EP-1673385-A4 | MACROCYCLIC PEPTIDES ACTIVE AGAINST THE HEPATITIS C VIRUS | BOEHRINGER INGELHEIM INT (DE) | 2006-10-04 | — | — | EP | disclosed |
| EP-1673385-A1 | MACROCYCLIC PEPTIDES ACTIVE AGAINST THE HEPATITIS C VIRUS | Boehringer Ingelheim International GmbH (DE) | 2006-06-28 | — | — | EP | disclosed |
| CN-1791599-A | Hepatitis c inhibitor compounds | BOEHRINGER INGELHEIM INT (DE) | 2006-06-21 | — | — | CN | disclosed |
| EP-1654261-A1 | HEPATITIS C INHIBITOR COMPOUNDS | Boehringer Ingelheim International GmbH (DE) | 2006-05-10 | — | — | EP | disclosed |
| WO-2005028501-A1 | MACROCYCLIC PEPTIDES ACTIVE AGAINST THE HEPATITIS C VIRUS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2005-03-31 | — | — | WO | disclosed |
| WO-2005028501-A1 | MACROCYCLIC PEPTIDES ACTIVE AGAINST THE HEPATITIS C VIRUS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2005-03-31 | — | — | WO | disclosed |
| US-20050020503-A1 | Hepatitis C inhibitor compounds | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2005-01-27 | — | — | US | disclosed |
| WO-2004103996-A1 | HEPATITIS C INHIBITOR COMPOUNDS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2004-12-02 | — | — | WO | disclosed |
| WO-2004103996-A1 | HEPATITIS C INHIBITOR COMPOUNDS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2004-12-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120269769-A1 | Hepatitis C Inhibitor Compounds | HAVCR2, CTRL, CTRC | GRM2 4857/4885LCK 4696/4885PDE4D 4640/4885 |
| US-20070243166-A1 | Hepatitis C Inhibitor Compounds | HAVCR2, CTRL, CTRC | GRM2 4857/4885LCK 4696/4885PDE4D 4640/4885 |
| US-20120034187-A1 | Hepatitis C Inhibitor Compounds | HAVCR2, CTRL, CTRC | GRM2 4857/4885LCK 4696/4885PDE4D 4640/4885 |
| US-20050020503-A1 | Hepatitis C inhibitor compounds | HAVCR2, CTRL, CTRC | GRM2 4857/4885LCK 4696/4885PDE4D 4640/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.